PMID- 16335858
OWN - NLM
STAT- MEDLINE
DCOM- 20051223
LR  - 20181113
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 65 Suppl 1
DP  - 2005
TI  - Healing of oesophagitis.
PG  - 51-7
AB  - The reflux oesophagitis treatment aims to achieve a rapid and sustained symptom 
      relief and a high percentage of lesion healing, apart from preventing the 
      relapses and complications of the disease. For that purpose it is essential to 
      maintain the oesophagic pH above 4 for as long as possible during the day and the 
      night. All these objectives are achieved with the use of the proton pump 
      inhibitors (PPI), which constitute the most effective drug group--being superior 
      to the rest of the antisecretory drugs, such as anti-H2, which are no longer in 
      use in this treatment. In moderate grades (grades A and B), all the PPIs used at 
      their usual dosages show a similar treatment efficacy within 8 weeks. In severe 
      cases (grades C and D), as well as those complicated with digestive haemorrhagia 
      or Barrett's oesophagus, esomeprazole shows a higher treatment efficacy than the 
      rest of the PPIs and is therefore the drug of choice. Furthermore, esomeprazole, 
      an active isomer of omeprazole, shows other properties such as a higher rate of 
      action, a lower interindividual variation and a more prolonged mode of action, 
      which all translate into additional advantages in comparison with the rest of the 
      PPIs.
FAU - Rodrigo, L
AU  - Rodrigo L
AD  - Digestive Diseases Service, Hospital Central de Asturias, Oviedo, Spain. 
      lrodrigos@terra.es
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Anti-Ulcer Agents/*administration & dosage
MH  - Esophagitis, Peptic/*drug therapy/pathology
MH  - Humans
MH  - Mucous Membrane/drug effects
MH  - *Proton Pump Inhibitors
MH  - Severity of Illness Index
RF  - 22
EDAT- 2005/12/13 09:00
MHDA- 2005/12/24 09:00
CRDT- 2005/12/13 09:00
PHST- 2005/12/13 09:00 [pubmed]
PHST- 2005/12/24 09:00 [medline]
PHST- 2005/12/13 09:00 [entrez]
AID - 10.2165/00003495-200565001-00008 [doi]
PST - ppublish
SO  - Drugs. 2005;65 Suppl 1:51-7. doi: 10.2165/00003495-200565001-00008.